Our overall results of enhancing immune cell cytotoxicity as an effect of ILK KD in the epithelial CRC cells suggests that targeting ILK may be promising for solid tumors and could show clinical benefit when combined with other approved therapies including chemotherapy, radiotherapy, and potentially immunotherapy. This evidence concerns the gene ILK and colorectal carcinoma.